AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$ABUS

Sawhney Roger sold (to issuer) $86K of ABUS

Sawhney Roger sold (to issuer) 17,142 shares of Arbutus Biopharma Corp (ABUS) at $5.00 on 2026-10-01.

Original reporting
SEC EDGAR · Sawhney Roger
Published Oct 7, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABUS
Neutral
high confidence
Mentioned
$ABUS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABUSNeutralLow
01

Why it matters

The modest sale is unlikely to move the stock significantly but provides transparency.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 3/10Timing: after market close on Oct 7, 2026

Background

Form 4 filings disclose insider transactions; this filing reports a director's sale.

Company-level read

Ticker impact

$ABUSNeutralHigh confidence
Context

Director Roger Sawhney sold 17,142 shares of ABUS for $85,710 on Oct 1, 2026, reducing his holding to 13,683 shares.

Expected impact

potential modest downward pressure as the market prices the insider sell.

Evidence & confidence

Form 4 filings are primary source; the transaction size is small relative to market cap, limiting impact.

Market effects

Sector

Minimal effect on the biotech sector; insider sales are routine.

Regional

No regional impact beyond the company's own stock.

Global

Not relevant to global markets.

Counterpoint

What could challenge this read

The sale could be a strategic reallocation rather than a lack of confidence.

Key entities

  • Company
    Arbutus Biopharma Corp

    US-listed biotech company (NASDAQ: ABUS).

  • Individual
    Roger Sawhney

    Director of Arbutus Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABUS insider trading history →

Related articles

OCT 22
$ABUSHighAI 8/10

Arbutus Biopharma Clears FDA Clinical Hold on AB-101 IND

Arbutus Biopharma (ABUS) can now advance U.S. clinical trials for AB-101 after the FDA lifted its clinical hold. The oral PD-L1 inhibitor completed a Phase 1a/1b trial, showing good tolerability and some efficacy in cHBV patients. The company is evaluating next steps for development.

tradingview.com1 min
OCT 22
$ABUSHighAI 8/10

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa

SEC EDGAR 8-K2 min